Efficacy and safety of lobeglitazone, a new Thiazolidinedione, as compared to the standard of care in type 2 diabetes mellitus: A systematic review and meta-analysis

• Published in: Diabetes & metabolic syndrome clinical research & reviews 2023-01, Vol.17 (1), p.102703-102703, Article 102703
• Main Authors: Joshi, Shashank R., Das, Saibal, Xaviar, Suja, Samajdar, Shambo Samrat, Saha, Indranil, Sarkar, Sougata, Mukherjee, Shatavisa, Tripathi, Santanu Kumar, Pal, Jyotirmoy, Chatterjee, Nandini
• Format: Article
• Language: English
• Subjects: Blood Glucose; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Glycated hemoglobin (HbA1C); Humans; Hypoglycemic Agents - therapeutic use; Lipid profile; Lipids; Lobeglitazone; Standard of Care; Thiazolidinedione; Thiazolidinediones - adverse effects
• ISSN: 1871-4021; 1878-0334
• DOI: 10.1016/j.dsx.2022.102703

This systematic review and meta-analysis was conducted to evaluate the efficacy and safety of lobeglitazone as compared to the standard of care (SOC) in patients with type 2 diabetes mellitus (T2DM). Databases were searched for relevant randomized controlled trials. The primary outcome was the comparison of the glycated hemoglobin (HbA1C) level after 24 weeks. Pooled mean differences and odds ratios were calculated using random-effects models. Of 267 studies that were screened, four were included. Treatment with adjunct lobeglitazone showed a reduction in the HbA1C level [mean difference: −0.23% (95% CI: −0.62 to 0.16); p = 0.24; i2: 87%; moderate GRADE (Grading of Recommendations Assessment, Development and. Evaluation) of evidence], fasting blood glucose level [mean difference: −7.12 mg/dl (95% CI: −20.09 to 5.85); p = 0.28; i2: 87%; moderate GRADE of evidence], and lipid profile as compared to those following treatment with the SOC; however, the changes were not statistically significant. The risk of hypoglycemia was significantly lower [odds ratio: 0.24 (95% CI: 0.08 to 0.70); p